{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-237203","form_type":"8-K","ticker":null,"cik":"0001618921","company_name":"Walgreens Boots Alliance, Inc.","filed_at":"2024-10-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.006090+00:00","generated_at":"2026-05-30T14:36:13.823409+00:00","sec_items":["2.02","7.01","2.05","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Walgreens reports FY2024 loss of $10.01/sh, plans to close 1,200-1,300 stores by 2027","bullets":["Q4 loss per share $3.48 (incl. $0.39 adj. EPS, down 40.8% YoY); revenue $37.5B (+6.0%).","FY2024 loss per share $10.01; adjusted EPS $2.88 (-27.9%); revenue $147.7B (+6.2%).","Footprint Optimization: close ~900-1,000 stores by FY2027, plus 300 from prior program for total 1,200-1,300; ~500 in FY2025.","Pre-tax charges $2.2-2.4B (lease $1.8-2.0B, impairments $300M, severance $100M); program accretive to cash flow starting FY2025.","FY2025 adjusted EPS guidance $1.40-1.80; expects Healthcare and Intl growth offset by U.S. Retail decline."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-237203","json":"https://secwatch.observer/filing/0001193125-24-237203.json","markdown":"https://secwatch.observer/filing/0001193125-24-237203.md","text":"https://secwatch.observer/filing/0001193125-24-237203.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1618921/000119312524237203/0001193125-24-237203-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1618921/000119312524237203/d870298d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T14:36:13.823409+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d7126faf234d769f50870827b817921a0d6aad9b","claim":"Walgreens Boots Alliance, Inc. announced a restructuring with charges of approximately $2.2 billion to $2.4 billion affecting U.S. Retail Pharmacy segment.","evidence_excerpt":"the workforce in those stores that are closed. The Company currently estimates that it will recognize cumulative pre-tax charges to its GAAP financial results of approximately $2.2 billion to $2.4 billion, including costs associated with lease obligations and other real estate costs, asset impairments, and employee severance and other exit costs. The Company","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1618921/000119312524237203/0001193125-24-237203-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $2.2 billion to $2.4 billion"},{"label":"Affected area","value":"U.S. Retail Pharmacy segment"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}